Gamida Cell - Cell and Immune Therapy Technologies

Enabling possibility

of life-changing cell therapies for patients with
cancer and rare genetic diseases

Learn More
Enabling possibility

of life-changing cell therapies for patients with
cancer and rare genetic diseases

Learn More
Enabling possibility

of life-changing cell therapies for patients with
cancer and rare genetic diseases

Learn More

Latest News

View All

Nov 1, 2018

Gamida Cell Announces New Translational Data for NiCord® to be Presented at ASH 2018 Annual Meeting

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

Gamida Cell to Present at Upcoming Investor Conferences

Gamida Cell Appoints Shai Lankry as Chief Financial Officer

Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

Gamida Cell World Cord Blood Day Conference, November 15, 2017

Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

Gamida Cell Announces $3.5 Million Grant from the Israeli Government

Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

Gamida Cell Announces $40 Million Private Financing

Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Committed to changing treatment paradigms

We are focused on developing novel cell therapies as a potentially curative approach for patients with serious medical conditions who have limited treatment options.

NiCord^®

For High-Risk Blood
Cancers and Bone Marrow
Failure Disorders

NAM-NK

For Blood Cancers
and Solid Tumors

Learn more about the cell therapies we are developing.

About Us

Our Technology

Our Pipeline

Enabling possibility

Enabling possibility

Enabling possibility

Latest News

Nov 1, 2018

Gamida Cell Announces New Translational Data for NiCord® to be Presented at ASH 2018 Annual Meeting

Sep 18, 2018

Gamida Cell Strengthens Its Board of Directors with Appointment of Robert Blum as Chairman

Aug 6, 2018

Gamida Cell Expands its Leadership Team with the Appointment of Jaren Madden as Vice President, Investor Relations and Corporate Communications

Jul 23, 2018

Gamida Cell Expands Leadership Team with Appointments of Tzvi Palash as Chief Operating Officer and John Schick as Vice President of Market Access

Jun 18, 2018

Gamida Cell to Present Preliminary Data from Ongoing Phase I NAM-NK Study at AACR International Meeting on Advances in Malignant Lymphoma

Apr 30, 2018

Gamida Cell to Present NiCord® Data at ISCT 2018 Annual Meeting

Apr 26, 2018

Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul Nee as Vice President of Marketing

Mar 19, 2018

Gamida Cell to Present Immune Reconstitution Data for its NiCord® Program at the 2018 EBMT Annual Meeting

Mar 16, 2018

Gamida Cell to Present at Upcoming Investor Conferences

Mar 15, 2018

Gamida Cell Appoints Shai Lankry as Chief Financial Officer

Feb 20, 2018

Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem Meetings

Jan 16, 2018

Gamida Cell Announces Initiation of a Phase I Study of NAM-NK Cells Immunotherapy Program for Non-Hodgkin Lymphoma and Multiple Myeloma

Dec 11, 2017

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

Nov 20, 2017

Gamida Cell Appoints Julian Adams, Ph.D., Chairman and Chief Executive Officer

Nov 1, 2017

Gamida Cell to Present New Data from Key Programs at 2017 ASH Annual Meeting

Sep 26, 2017

Gamida Cell World Cord Blood Day Conference, November 15, 2017

Aug 21, 2017

Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS

Jul 20, 2017

Gamida Cell Announces $3.5 Million Grant from the Israeli Government

Jul 10, 2017

Gamida Cell Inc. Names Ronit Simantov, M.D. as Chief Medical Officer

Jun 19, 2017

Gamida Cell Announces $40 Million Private Financing

News Spotlight

Oct 26, 2018

Gamida Cell Announces Pricing of Initial Public Offering

Committed to changing treatment paradigms

NiCord®

NAM-NK

Learn more about the cell therapies we are developing.

About Us

Our Technology

Our Pipeline

NiCord^®